In Barrett’s esophagus, the stratified squamous epithelium lining the esophagus is replaced by specialized intestinal-type columnar epithelium. The prevalence of Barrett’s esophagus has ranged from 0.9% to 4.5%. The rate of progression from Barrett’s esophagus to esophageal adenocarcinoma is 0.5% per patient-year. Proton-pump inhibitors are the mainstay of symptom control in Barrett’s patients. Nondysplastic Barrett’s and Barrett’s with low-grade dysplasia (LGD) are typically managed by periodic surveillance. Radiofrequency ablation is being evaluated as a modality for managing nondysplastic Barrett’s and Barrett’s with LGD. The options for the management of Barrett’s patients with high-grade dysplasia (HGD) include endoscopic therapy, surgery, and intensive surveillance until biopsy reveals adenocarcinoma. Endoscopic therapy involves endoscopic mucosal resection (EMR) and ablation. More aggressive techniques such as endoscopic submucosal dissection and larger segment endoscopic mucosal resection are under study. In this review, we discuss the diagnosis and management of Barrett’s esophagus. The recommendations from the major gastroenterologic societies and the current and investigational endoscopic modalities for the management of Barrett’s esophagus with and without dysplasia are reviewed.
Abrams, J.A., Fields, S., Lightdale, C.J. and Neugut, A.I. ( 2008) Racial and ethnic disparities in the prevalence of Barrett’s esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol6: 30-34.
Baust, J.G. and Gage, A.A. ( 2005) The molecular basis of cryosurgery. BJU Int95: 1187-1191.
4.
Buskens, C.J., Westerterp, M., Lagarde, S.M., Bergman, J.J., Ten Kate, F.J. and Van Lanschot, J.J. ( 2004) Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc60: 703-710.
5.
Cameron, A.J., Zinsmeister, A.R., Ballard, D.J. and Carney, J.A. ( 1990) Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology99: 918-922.
6.
Chiba, N. ( 1997) Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol11(Suppl B): 66B-73B.
7.
Cook, M.B., Wild, C.P. and Forman, D. ( 2005) A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and non-erosive reflux disease. Am J Epidemiol162: 1050-1061.
8.
Drewitz, D.J., Sampliner, R.E. and Garewal, H.S. ( 1997) The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol92: 212-215.
9.
Dumot, J.A. and Greenwald, B.D. ( 2008) Argon plasma coagulation, bipolar cautery, and cryotherapy: ABC’s of ablative techniques. Endoscopy40: 1026-1032.
10.
Edwards, M.J., Gable, D.R., Lentsch, A.B. and Richardson, J.D. ( 1996) The rationale for esophagectomy as the optimal therapy for Barrett’s esophagus with high-grade dysplasia. Ann Surg223: 585-589; discussion 589-591.
11.
Eguchi, T., Nakanishi, Y., Shimoda, T., Iwasaki, M., Igaki, H., Tachimori, Y. et al. (2006) Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol19: 475-480.
12.
El-Serag, H.B., Aguirre, T.V., Davis, S., Kuebeler, M., Bhattacharyya, A. and Sampliner, R.E. ( 2004) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol99: 1877-1883.
13.
Ell, C., May, A., Gossner, L., Pech, O., Gunter, E., Mayer, G. et al. (2000) Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology118: 670-677.
14.
Ell, C., May, A., Pech, O., Gossner, L., Guenter, E., Behrens, A. et al. (2007) Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc65: 3-10.
15.
Endo, M., Yoshino, K., Kawano, T., Nagai, K. and Inoue, H. ( 2000) Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus13: 125-129.
16.
Fackler, W.K., Ours, T.M., Vaezi, M.F. and Richter, J.E. ( 2002) Long-term effect of H2ra therapy on nocturnal gastric acid breakthrough. Gastroenterology122: 625-632.
Fleischer, D.E., Overholt, B.F., Sharma, V.K., Reymunde, A., Kimmey, M.B., Chuttani, R. et al. (2008) Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc68: 867-876.
19.
Fleischer, D.E., Wang, G.Q., Dawsey, S., Tio, T.L., Newsome, J., Kidwell, J. et al. (1996) Tissue band ligation followed by snare resection (band and snare): a new technique for tissue acquisition in the esophagus. Gastrointest Endosc44: 68-72.
20.
Gage, A.A. and Baust, J. ( 1998) Mechanisms of tissue injury in cryosurgery. Cryobiology37: 171-186.
21.
Ganz, R.A., Overholt, B.F., Sharma, V.K., Fleischer, D.E., Shaheen, N.J., Lightdale, C.J. et al. (2008) Circumferential ablation of Barrett’s esophagus that contains high-grade dysplasia: a U.S. multicenter registry . Gastrointest Endosc68: 35-40.
22.
Greene, F.L. for the American Joint Committee on Cancer and American Cancer Society. (2002) AJCC Cancer Staging Manual, 6th edn, Springer: New York.
23.
Hampel, H., Abraham, N.S. and El-Serag, H.B. ( 2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med143: 199-211.
24.
Hirota, W.K., Loughney, T.M., Lazas, D.J., Maydonovitch, C.L., Rholl, V. and Wong, R.K. ( 1999) Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data . Gastroenterology116: 277-285.
25.
Hirota, W.K., Zuckerman, M.J., Adler, D.G., Davila, R.E., Egan, J., Leighton, J.A. et al. (2006) ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc63: 570-580.
26.
Inoue, H., Takeshita, K., Hori, H., Muraoka, Y., Yoneshima, H. and Endo, M. ( 1993) Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc39: 58-62.
27.
Isenberg, G., Sivak Jr, M.V., Chak, A., Wong, R.C., Willis, J.E., Wolf, B. et al. (2005) Accuracy of endoscopic optical coherence tomography in the detection of dysplasia in Barrett’s esophagus: a prospective, double-blinded study. Gastrointest Endosc62: 825-831.
28.
Johnston, M.H., Eastone, J.A., Horwhat, J.D., Cartledge, J., Mathews, J.S. and Foggy, J.R. ( 2005) Cryoablation of Barrett’s esophagus: a pilot study . Gastrointest Endosc62: 842-848.
Kaltenbach, T., Crockett, S. and Gerson, L.B. ( 2006) Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med166: 965-971.
31.
Kara, M.A., Ennahachi, M., Fockens, P., Ten Kate, F.J. and Bergman, J.J. ( 2006) Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett’s esophagus by using narrow band imaging. Gastrointest Endosc64: 155-166.
32.
Khan, M., Santana, J., Donnellan, C., Preston, C. and Moayyedi, P. ( 2007) Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst RevCD003244.
33.
Kiesslich, R., Gossner, L., Goetz, M., Dahlmann, A., Vieth, M., Stolte, M. et al. (2006) In vivo histology of Barrett’s esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol4: 979-987.
34.
Liu, L., Hofstetter, W.L., Rashid, A., Swisher, S.G., Correa, A.M., Ajani, J.A. et al. (2005) Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma . Am J Surg Pathol29: 1079-1085.
35.
May, A., Gossner, L., Behrens, A., Kohnen, R., Vieth, M., Stolte, M. et al. (2003) A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc58: 167-175.
36.
May, A., Gossner, L., Pech, O., Fritz, A., Gunter, E., Mayer, G. et al. (2002) Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol14: 1085-1091.
37.
Mino-Kenudson, M., Hull, M.J., Brown, I., Muzikansky, A., Srivastava, A., Glickman, J. et al. (2007) EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc66: 660-666; quiz 767, 769.
38.
Mirnezami, R., Rohatgi, A., Sutcliffe, R.P., Hamouda, A. and Mason, R.C.(2009) Transhiatal oesophagectomy: treatment of choice for high-grade dysplasia . Eur J Cardiothorac Surg36: 364-367.
39.
Montgomery, E., Bronner, M.P., Goldblum, J.R., Greenson, J.K., Haber, M.M., Hart, J. et al. (2001) Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol32: 368-378.
40.
Ngamruengphong, S., Sharma, V.K. and Das, A.(2009) Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: a meta-analysis . Gastrointest Endosc69: 1021-1028.
41.
Nijhawan, P.K. and Wang, K.K. ( 2000) Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett’s esophagus. Gastrointest Endosc52: 328-332.
42.
O’connor, J.B., Falk, G.W. and Richter, J.E. ( 1999) The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus: report on the Cleveland Clinic Barrett’s Esophagus Registry . Am J Gastroenterol94: 2037-2042.
43.
Ormsby, A.H., Petras, R.E., Henricks, W.H., Rice, T.W., Rybicki, L.A., Richter, J.E. et al. (2002) Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut51: 671-676.
44.
Overholt, B.F., Lightdale, C.J., Wang, K.K., Canto, M.I., Burdick, S., Haggitt, R.C. et al. (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc62: 488-498.
45.
Paull, A., Trier, J.S., Dalton, M.D., Camp, R.C., Loeb, P. and Goyal, R.K. ( 1976) The histologic spectrum of Barrett’s esophagus. N Engl J Med295: 476-480.
46.
Pech, O., Behrens, A., May, A., Nachbar, L., Gossner, L., Rabenstein, T. et al. (2008) Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus . Gut57: 1200-1206.
47.
Pech, O., Gossner, L., May, A., Rabenstein, T., Vieth, M., Stolte, M. et al. (2005) Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc62: 24-30.
48.
Peghini, P.L., Katz, P.O. and Castell, D.O. ( 1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology115: 1335-1339.
49.
Prasad, G.A., Wang, K.K., Buttar, N.S., Wongkeesong, L.M., Krishnadath, K.K., Nichols III, F.C. et al. (2007) Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus. Gastroenterology132: 1226-1233.
50.
Reid, B.J., Blount, P.L., Feng, Z. and Levine, D.S. ( 2000) Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia. Am J Gastroenterol95: 3089-3096.
51.
Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E. et al. (2005) Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology129: 1825-1831.
52.
Schlemper, R.J., Riddell, R.H., Kato, Y., Borchard, F., Cooper, H.S., Dawsey, S.M. et al. (2000) The Vienna classification of gastrointestinal epithelial neoplasia. Gut47: 251-255.
53.
Schnell, T.G., Sontag, S.J., Chejfec, G., Aranha, G., Metz, A., O’connell, S. et al. (2001) Long-term non-surgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology120: 1607-1619.
54.
Shaheen, N.J. and Richter, J.E.(2009) Barrett’s oesophagus. Lancet373: 850-861.
55.
Shaheen, N.J., Sharma, P., Overholt, B.F., Wolfsen, H.C., Sampliner, R.E., Wang, K.K. et al. (2009) Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med360: 2277-2288.
56.
Sharma, P., Falk, G.W., Weston, A.P., Reker, D., Johnston, M. and Sampliner, R.E. ( 2006) Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol4: 566-572.
57.
Sharma, P., Mcquaid, K., Dent, J., Fennerty, M.B., Sampliner, R., Spechler, S. et al. (2004) A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology127: 310-330.
58.
Sharma, V.K., Jae Kim, H., Das, A., Wells, C.D., Nguyen, C.C. and Fleischer, D.E.(2009) Circumferential and focal ablation of Barrett’s esophagus containing dysplasia. Am J Gastroenterol104: 310-317.
Shimada, H., Nabeya, Y., Matsubara, H., Okazumi, S., Shiratori, T., Shimizu, T. et al. (2006) Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg191: 250-254.
61.
Skacel, M., Petras, R.E., Gramlich, T.L., Sigel, J.E., Richter, J.E. and Goldblum, J.R. ( 2000) The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol95: 3383-3387.
62.
Souza, R.F., Shewmake, K., Terada, L.S. and Spechler, S.J. ( 2002) Acid exposure activates the mitogen-activated protein kinase pathways in Barrett’s esophagus. Gastroenterology122: 299-307.
Stahl, M. and Oliveira, J.(2009) Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol20(Suppl 4): 32-33.
65.
Takeshita, K., Tani, M., Inoue, H., Saeki, I., Hayashi, S., Honda, T. et al. (1997) Endoscopic treatment of early oesophageal or gastric cancer. Gut40: 123-127.
66.
Vaezi, M.F. and Richter, J.E. ( 1996) Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology111: 1192-1199.
67.
Van Laethem, J.L., Peny, M.O., Salmon, I., Cremer, M. and Deviere, J. ( 2000) Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus. Gut46: 574-577.
68.
Van Lanschot, J.J., Hulscher, J.B., Buskens, C.J., Tilanus, H.W., Ten Kate, F.J. and Obertop, H. ( 2001) Hospital volume and hospital mortality for esophagectomy . Cancer91: 1574-1578.
69.
Velanovich, V. ( 2009) Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus: initial results and lessons learned. Surg Endosc23: 2175-2180.
70.
Vieth, M., Ell, C., Gossner, L., May, A. and Stolte, M. ( 2004) Histological analysis of endoscopic resection specimens from 326 patients with Barrett’s esophagus and early neoplasia. Endoscopy36: 776-781.
71.
Viklund, P., Wengstrom, Y., Rouvelas, I., Lindblad, M. and Lagergren, J. ( 2006) Quality of life and persisting symptoms after oesophageal cancer surgery. Eur J Cancer42: 1407-1414.
72.
Wang, K.K. and Sampliner, R.E. ( 2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol103: 788-797.
73.
Westerterp, M., Koppert, L.B., Buskens, C.J., Tilanus, H.W., Ten Kate, F.J., Bergman, J.J. et al. (2005) Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows ‘Arch446: 497-504.
74.
Weston, A.P., Sharma, P., Topalovski, M., Richards, R., Cherian, R. and Dixon, A. ( 2000) Long-term follow-up of Barrett’s high-grade dysplasia . Am J Gastroenterol95: 1888-1893.
75.
Willingham, F.F., Gee, D.W., Sylla, P., Lauwers, G.Y., Rattner, D.W. and Brugge, W.R.(2009) En bloc esophageal mucosectomy for concentric circumferential mucosal resection (with video). Gastrointest Endosc69: 147-151.
76.
Yoshida, M., Hanashi, T., Momma, K., Yamada, Y., Sakaki, N., Koike, M. et al. (1995) [Endoscopic mucosal resection for radical treatment of esophageal cancer]. Gan To Kagaku Ryoho22: 847-854.
77.
Yoshinaga, S., Gotoda, T., Kusano, C., Oda, I., Nakamura, K. and Takayanagi, R. ( 2008) Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction. Gastrointest Endosc67: 202-209.
